{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:22:46Z","timestamp":1793114566077,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T00:00:00Z","timestamp":1698451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T00:00:00Z","timestamp":1698451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["115372"],"award-info":[{"award-number":["115372"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["115952"],"award-info":[{"award-number":["115952"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005760","name":"University of Gothenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005760","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To investigate the impact of reduced injected doses on the quantitative and qualitative assessment of the amyloid PET tracers [<jats:sup>18<\/jats:sup>F]flutemetamol and [<jats:sup>18<\/jats:sup>F]florbetaben.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Cognitively impaired and unimpaired individuals (<jats:italic>N<\/jats:italic>\u2009=\u2009250, 36% A\u03b2-positive) were included and injected with [<jats:sup>18<\/jats:sup>F]flutemetamol (<jats:italic>N<\/jats:italic>\u2009=\u2009175) or [<jats:sup>18<\/jats:sup>F]florbetaben (<jats:italic>N<\/jats:italic>\u2009=\u200975). PET scans were acquired in list-mode (90\u2013110\u00a0min post-injection) and reduced-dose images were simulated to generate images of 75, 50, 25, 12.5 and 5% of the original injected dose. Images were reconstructed using vendor-provided reconstruction tools and visually assessed for A\u03b2-pathology. SUVRs were calculated for a global cortical and three smaller regions using a cerebellar cortex reference tissue, and Centiloid was computed. Absolute and percentage differences in SUVR and CL were calculated between dose levels, and the ability to discriminate between A\u03b2- and A\u03b2\u2009+\u2009scans was evaluated using ROC analyses. Finally, intra-reader agreement between the reduced dose and 100% images was evaluated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>At 5% injected dose, change in SUVR was 3.72% and 3.12%, with absolute change in Centiloid 3.35CL and 4.62CL, for [<jats:sup>18<\/jats:sup>F]flutemetamol and [<jats:sup>18<\/jats:sup>F]florbetaben, respectively. At 12.5% injected dose, percentage change in SUVR and absolute change in Centiloid were\u2009&lt;\u20091.5%. AUCs for discriminating A\u03b2- from A\u03b2\u2009+\u2009scans were high (AUC\u2009\u2265\u20090.94) across dose levels, and visual assessment showed intra-reader agreement of\u2009&gt;\u200980% for both tracers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This proof-of-concept study showed that for both [<jats:sup>18<\/jats:sup>F]flutemetamol and [<jats:sup>18<\/jats:sup>F]florbetaben, adequate quantitative and qualitative assessments can be obtained at 12.5% of the original injected dose. However, decisions to reduce the injected dose should be made considering the specific clinical or research circumstances.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00259-023-06481-0","type":"journal-article","created":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T08:02:15Z","timestamp":1698480135000},"page":"734-748","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Impact of simulated reduced injected dose on the assessment of amyloid PET scans"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4818-4270","authenticated-orcid":false,"given":"Peter","family":"Young","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7769-8329","authenticated-orcid":false,"given":"Fiona","family":"Heeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3731-3612","authenticated-orcid":false,"given":"Jan","family":"Axelsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6263-1762","authenticated-orcid":false,"given":"Lyduine E.","family":"Collij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Hitzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8437-2060","authenticated-orcid":false,"given":"Amirhossein","family":"Sanaat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7306-5775","authenticated-orcid":false,"given":"Aida","family":"Ni\u00f1erola-Baizan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4190-2425","authenticated-orcid":false,"given":"Andr\u00e9s","family":"Perissinotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8324-7399","authenticated-orcid":false,"given":"Mark","family":"Lubberink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6419-1753","authenticated-orcid":false,"given":"Giovanni B.","family":"Frisoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7559-5297","authenticated-orcid":false,"given":"Habib","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3543-3706","authenticated-orcid":false,"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0726-723X","authenticated-orcid":false,"given":"Gill","family":"Farrar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0209-3127","authenticated-orcid":false,"given":"Suzanne","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6155-0642","authenticated-orcid":false,"given":"Juan Domingo","family":"Gispert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2422-698X","authenticated-orcid":false,"given":"Valentina","family":"Garibotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5389-1578","authenticated-orcid":false,"given":"Anna","family":"Rieckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7800-1781","authenticated-orcid":false,"given":"Michael","family":"Sch\u00f6ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the AMYPAD consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,28]]},"reference":[{"key":"6481_CR1","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1016\/j.jalz.2012.10.007","volume":"9","author":"KA Johnson","year":"2013","unstructured":"Johnson KA, Sperling RA, Gidicsin CM, et al. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer\u2019s disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement. 2013;9:S72\u201383.","journal-title":"Alzheimers Dement"},{"key":"6481_CR2","first-page":"414","volume":"8","author":"SL Lowe","year":"2021","unstructured":"Lowe SL, Duggan Evans C, Shcherbinin S, et al. Donanemab (LY3002813) Phase 1b Study in Alzheimer\u2019s Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging. J Prev Alzheimers Dis. 2021;8:414\u201324.","journal-title":"J Prev Alzheimers Dis"},{"key":"6481_CR3","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.3390\/diagnostics12061357","volume":"12","author":"S Chung","year":"2022","unstructured":"Chung S, Kim H-J, Jo S, et al. Patterns of Focal Amyloid Deposition Using 18F-Florbetaben PET in Patients with Cognitive Impairment. Diagnostics. 2022;12:1357.","journal-title":"Diagnostics"},{"key":"6481_CR4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13550-018-0456-7","volume":"8","author":"MR Battle","year":"2018","unstructured":"Battle MR, Pillay LC, Lowe VJ, et al. Centiloid scaling for quantification of brain amyloid with [18F]flutemetamol using multiple processing methods. EJNMMI Res. 2018;8:107.","journal-title":"EJNMMI Res"},{"key":"6481_CR5","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1007\/s00259-021-05311-5","volume":"48","author":"M Bucci","year":"2021","unstructured":"Bucci M, Savitcheva I, Farrar G, et al. A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol amyloid PET images. Eur J Nucl Med Mol Imaging. 2021;48:2183\u201399.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6481_CR6","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s00259-015-3208-1","volume":"43","author":"K Heurling","year":"2016","unstructured":"Heurling K, Leuzy A, Zimmer ER, Lubberink M, Nordberg A. Imaging \u03b2-amyloid using [18F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis. Eur J Nucl Med Mol Imaging. 2016;43:362\u201373.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6481_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2214\/ajr.177.1.1770031","volume":"177","author":"JS Keppler","year":"2001","unstructured":"Keppler JS, Conti PS. A Cost Analysis of Positron Emission Tomography. Am J Roentgenol. 2001;177:31\u201340.","journal-title":"Am J Roentgenol"},{"key":"6481_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1053\/j.sult.2009.09.005","volume":"31","author":"CE Devine","year":"2010","unstructured":"Devine CE, Mawlawi O. Radiation Safety With Positron Emission Tomography and Computed Tomography. Semin Ultrasound CT MRI. 2010;31:39\u201345.","journal-title":"Semin Ultrasound CT MRI"},{"key":"6481_CR9","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/sj.bjc.6604825","volume":"100","author":"CR Muirhead","year":"2009","unstructured":"Muirhead CR, O\u2019Hagan JA, Haylock RGE, et al. Mortality and cancer incidence following occupational radiation exposure: third analysis of the National Registry for Radiation Workers. Br J Cancer. 2009;100:206\u201312.","journal-title":"Br J Cancer"},{"key":"6481_CR10","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.clon.2011.01.159","volume":"23","author":"SJ Schonfeld","year":"2011","unstructured":"Schonfeld SJ, Lee C, Berrington de Gonz\u00e1lez A. Medical Exposure to Radiation and Thyroid Cancer. Clin Oncol. 2011;23:244\u201350.","journal-title":"Clin Oncol."},{"key":"6481_CR11","first-page":"723","volume":"54","author":"GA Becker","year":"2013","unstructured":"Becker GA, Ichise M, Barthel H, et al. PET quantification of 18F-florbetaben binding to \u03b2-amyloid deposits in human brains. J Nucl Med Off Publ Soc Nucl Med. 2013;54:723\u201331.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"6481_CR12","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.2967\/jnumed.109.063305","volume":"50","author":"N Nelissen","year":"2009","unstructured":"Nelissen N, Laere KV, Thurfjell L, et al. Phase 1 Study of the Pittsburgh Compound B Derivative 18F-Flutemetamol in Healthy Volunteers and Patients with Probable Alzheimer Disease. J Nucl Med. 2009;50:1251\u20139.","journal-title":"J Nucl Med"},{"key":"6481_CR13","doi-asserted-by":"publisher","first-page":"60S","DOI":"10.2967\/jnumed.121.263201","volume":"63","author":"RE Carson","year":"2022","unstructured":"Carson RE, Naganawa M, Toyonaga T, et al. Imaging of Synaptic Density in Neurodegenerative Disorders. J Nucl Med. 2022;63:60S-67S.","journal-title":"J Nucl Med"},{"key":"6481_CR14","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/WCO.0000000000001035","volume":"35","author":"GC Petersen","year":"2022","unstructured":"Petersen GC, Roytman M, Chiang GC, Li Y, Gordon ML, Franceschi AM. Overview of tau PET molecular imaging. Curr Opin Neurol. 2022;35:230\u20139.","journal-title":"Curr Opin Neurol"},{"key":"6481_CR15","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1007\/s00259-021-05390-4","volume":"48","author":"N Aide","year":"2021","unstructured":"Aide N, Lasnon C, Kesner A, et al. New PET technologies \u2013 embracing progress and pushing the limits. Eur J Nucl Med Mol Imaging. 2021;48:2711\u201326.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6481_CR16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1053\/j.semnuclmed.2015.09.006","volume":"46","author":"PJ Slomka","year":"2016","unstructured":"Slomka PJ, Pan T, Germano G. Recent Advances and Future Progress in PET Instrumentation. Semin Nucl Med. 2016;46:5\u201319.","journal-title":"Semin Nucl Med"},{"key":"6481_CR17","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2967\/jnumed.119.226498","volume":"60","author":"RD Badawi","year":"2019","unstructured":"Badawi RD, Shi H, Hu P, et al. First Human Imaging Studies with the EXPLORER Total-Body PET Scanner*. J Nucl Med. 2019;60:299\u2013303.","journal-title":"J Nucl Med"},{"key":"6481_CR18","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ana.22068","volume":"68","author":"R Vandenberghe","year":"2010","unstructured":"Vandenberghe R, Van Laere K, Ivanoiu A, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial. Ann Neurol. 2010;68:319\u201329.","journal-title":"Ann Neurol"},{"key":"6481_CR19","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1007\/s00259-014-2842-3","volume":"41","author":"K Herholz","year":"2014","unstructured":"Herholz K, Evans R, Anton-Rodriguez J, Hinz R, Matthews JC. The effect of 18F-florbetapir dose reduction on region-based classification of cortical amyloid deposition. Eur J Nucl Med Mol Imaging. 2014;41:2144\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6481_CR20","first-page":"848","volume":"58","author":"SS Bohorquez","year":"2017","unstructured":"Bohorquez SS, Barret O, Tamagnan G, et al. Assessing optimal injected dose for tau PET imaging using [18F]GTP1 (Genentech Tau Probe 1). J Nucl Med. 2017;58:848\u2013848.","journal-title":"J Nucl Med"},{"key":"6481_CR21","first-page":"269","volume":"6","author":"D F\u00e4llmar","year":"2016","unstructured":"F\u00e4llmar D, Lilja J, Kilander L, et al. Validation of true low-dose 18F-FDG PET of the brain. Am J Nucl Med Mol Imaging. 2016;6:269\u201376.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"6481_CR22","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ejmp.2018.01.021","volume":"46","author":"E Prieto","year":"2018","unstructured":"Prieto E, Garc\u00eda-Velloso MJ, Rodr\u00edguez-Fraile M, et al. Significant dose reduction is feasible in FDG PET\/CT protocols without compromising diagnostic quality. Phys Med. 2018;46:134\u20139.","journal-title":"Phys Med"},{"key":"6481_CR23","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s11307-019-01398-3","volume":"22","author":"M Soret","year":"2020","unstructured":"Soret M, Piekarski E, Yeni N, et al. Dose Reduction in Brain [18F]FDG PET\/MRI: Give It Half a Chance. Mol Imaging Biol. 2020;22:695\u2013702.","journal-title":"Mol Imaging Biol"},{"key":"6481_CR24","first-page":"15","volume":"19","author":"S Gatidis","year":"2016","unstructured":"Gatidis S, W\u00fcrslin C, Seith F, Sch\u00e4fer JF. Towards tracer dose reduction in PET studies: Simulation of dose reduction by retrospective randomized undersampling of list-mode data. Hell J Nucl Med. 2016;19:15\u20138.","journal-title":"Hell J Nucl Med."},{"key":"6481_CR25","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.2967\/jnumed.114.139147","volume":"55","author":"M Oehmigen","year":"2014","unstructured":"Oehmigen M, Ziegler S, Jakoby BW, Georgi J-C, Paulus DH, Quick HH. Radiotracer Dose Reduction in Integrated PET\/MR: Implications from National Electrical Manufacturers Association Phantom Studies. J Nucl Med. 2014;55:1361\u20137.","journal-title":"J Nucl Med"},{"key":"6481_CR26","doi-asserted-by":"crossref","unstructured":"Mehranian A, Bland J, McGinnity CJ, Hammers A, Reader AJ. Clinical Assessment Of MR-Assisted PET Image Reconstruction Algorithms for Low-Dose Brain PET Imaging. In: 2019 IEEE Nuclear Science Symposium and Medical Imaging Conference (NSS\/MIC). 2019:1\u20133.","DOI":"10.1109\/NSS\/MIC42101.2019.9059655"},{"key":"6481_CR27","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1109\/TMI.2010.2048119","volume":"29","author":"C Lartizien","year":"2010","unstructured":"Lartizien C, Aubin J-B, Buvat I. Comparison of bootstrap resampling methods for 3-D PET imaging. IEEE Trans Med Imaging. 2010;29:1442\u201354.","journal-title":"IEEE Trans Med Imaging"},{"key":"6481_CR28","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jalz.2018.09.003","volume":"15","author":"GB Frisoni","year":"2019","unstructured":"Frisoni GB, Barkhof F, Altomare D, et al. AMYPAD Diagnostic and Patient Management Study: Rationale and design. Alzheimers Dement J Alzheimers Assoc. 2019;15:388\u201399.","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"6481_CR29","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/alz.12069","volume":"16","author":"I Lopes Alves","year":"2020","unstructured":"Lopes Alves I, Collij LE, Altomare D, et al. Quantitative amyloid PET in Alzheimer\u2019s disease: the AMYPAD prognostic and natural history study. Alzheimers Dement. 2020;16:750\u20138.","journal-title":"Alzheimers Dement"},{"key":"6481_CR30","doi-asserted-by":"publisher","first-page":"118775","DOI":"10.1016\/j.neuroimage.2021.118775","volume":"246","author":"L Iaccarino","year":"2022","unstructured":"Iaccarino L, La Joie R, Koeppe R, et al. rPOP: Robust PET-only processing of community acquired heterogeneous amyloid-PET data. Neuroimage. 2022;246:118775.","journal-title":"Neuroimage"},{"key":"6481_CR31","doi-asserted-by":"publisher","first-page":"119527","DOI":"10.1016\/j.neuroimage.2022.119527","volume":"262","author":"P Bourgeat","year":"2022","unstructured":"Bourgeat P, Dor\u00e9 V, Burnham SC, et al. \u03b2-amyloid PET harmonisation across longitudinal studies: Application to AIBL, ADNI and OASIS3. Neuroimage. 2022;262:119527.","journal-title":"Neuroimage"},{"key":"6481_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC, et al. The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11:1-15.e4.","journal-title":"Alzheimers Dement"},{"key":"6481_CR33","doi-asserted-by":"publisher","first-page":"103321","DOI":"10.1016\/j.nicl.2023.103321","volume":"37","author":"ES Luckett","year":"2023","unstructured":"Luckett ES, Schaeverbeke J, De Meyer S, et al. Longitudinal changes in 18F-flutemetamol amyloid load in cognitively intact APOE4 carriers versus noncarriers: methodological considerations. Neuroimage Clin. 2023;37:103321.","journal-title":"Neuroimage Clin."},{"key":"6481_CR34","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.neuroimage.2006.01.021","volume":"31","author":"RS Desikan","year":"2006","unstructured":"Desikan RS, S\u00e9gonne F, Fischl B, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31:968\u201380.","journal-title":"Neuroimage"},{"key":"6481_CR35","doi-asserted-by":"publisher","first-page":"e1538","DOI":"10.1212\/WNL.0000000000010256","volume":"95","author":"LE Collij","year":"2020","unstructured":"Collij LE, Heeman F, Salvad\u00f3 G, et al. Multitracer model for staging cortical amyloid deposition using PET imaging. Neurology. 2020;95:e1538\u201353.","journal-title":"Neurology"},{"key":"6481_CR36","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/s41467-017-01150-x","volume":"8","author":"S Palmqvist","year":"2017","unstructured":"Palmqvist S, Sch\u00f6ll M, Strandberg O, et al. Earliest accumulation of \u03b2-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat Commun. 2017;8:1214.","journal-title":"Nat Commun"},{"key":"6481_CR37","unstructured":"Vizamyl. [Internet]. [cited 2023 March 6] ] https:\/\/www.gehealthcare.in\/-\/jssmedia\/widen\/2018\/01\/25\/0204\/gehealthcarecom\/migrated\/2018\/02\/19\/0834\/gatekeeperclinical-product-infovizamylgehealthcarevizamylprescribinginformationpdf.pdf?rev=-1&hash=6389279151DA03442BD67470D93050F3."},{"key":"6481_CR38","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.1007\/s00259-022-05784-y","volume":"49","author":"HG Pemberton","year":"2022","unstructured":"Pemberton HG, Collij LE, Heeman F, et al. Quantification of amyloid PET for future clinical use: a state-of-the-art review. Eur J Nucl Med Mol Imaging. 2022;49:3508\u201328.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"6481_CR39","unstructured":"Presotto L, Shekari M, Collij LE, et al. Amyloid PET centiloid: impact of calibration and processing steps. CTAD. 2022; p 83."},{"key":"6481_CR40","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.nicl.2018.04.022","volume":"19","author":"Y Su","year":"2018","unstructured":"Su Y, Flores S, Hornbeck RC, et al. Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies. NeuroImage Clin. 2018;19:406\u201316.","journal-title":"NeuroImage Clin"},{"key":"6481_CR41","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13550-020-00714-1","volume":"10","author":"F Heeman","year":"2020","unstructured":"Heeman F, Hendriks J, Lopes Alves I, et al. [11C]PIB amyloid quantification: effect of reference region selection. EJNMMI Res. 2020;10:123.","journal-title":"EJNMMI Res"},{"key":"6481_CR42","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13195-021-00819-2","volume":"13","author":"I Lopes Alves","year":"2021","unstructured":"Lopes Alves I, Heeman F, Collij LE, et al. Strategies to reduce sample sizes in Alzheimer\u2019s disease primary and secondary prevention trials using longitudinal amyloid PET imaging. Alzheimers Res Ther. 2021;13:82.","journal-title":"Alzheimers Res Ther"},{"key":"6481_CR43","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1177\/0271678X19879226","volume":"40","author":"T Timmers","year":"2020","unstructured":"Timmers T, Ossenkoppele R, Visser D, et al. Test-retest repeatability of [18F]Flortaucipir PET in Alzheimer\u2019s disease and cognitively normal individuals. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab. 2020;40:2464\u201374.","journal-title":"J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab"},{"key":"6481_CR44","doi-asserted-by":"crossref","unstructured":"C. Rowe C, Rowe CC, Pejoska S, et al. Test-retest variability studies in Alzheimer\u2019s disease and normal ageing of the new amyloid imaging agent [18F]BAY 94\u20139172. Alzheimers Dement 2009;5:P262-P263.","DOI":"10.1016\/j.jalz.2009.04.318"},{"key":"6481_CR45","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1007\/s00259-020-05174-2","volume":"48","author":"LE Collij","year":"2021","unstructured":"Collij LE, Salvad\u00f3 G, Shekari M, et al. Visual assessment of [18F]flutemetamol PET images can detect early amyloid pathology and grade its extent. Eur J Nucl Med Mol Imaging. 2021;48:2169\u201382.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6481_CR46","doi-asserted-by":"publisher","first-page":"e352","DOI":"10.1016\/j.jns.2013.07.1294","volume":"333","author":"Z Walker","year":"2013","unstructured":"Walker Z, Inglis F, Sadowsky C, et al. Reproducibility of [18f]flutemetamol pet amyloid image interpretation. J Neurol Sci. 2013;333:e352.","journal-title":"J Neurol Sci"},{"key":"6481_CR47","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2967\/jnumed.118.211532","volume":"60","author":"LE Collij","year":"2019","unstructured":"Collij LE, Konijnenberg E, Reimand J, et al. Assessing Amyloid Pathology in Cognitively Normal Subjects Using 18F-Flutemetamol PET: Comparing Visual Reads and Quantitative Methods. J Nucl Med. 2019;60:541\u20137.","journal-title":"J Nucl Med"},{"key":"6481_CR48","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40336-015-0102-6","volume":"3","author":"O Sabri","year":"2015","unstructured":"Sabri O, Seibyl J, Rowe C, Barthel H. Beta-amyloid imaging with florbetaben. Clin Transl Imaging. 2015;3:13\u201326.","journal-title":"Clin Transl Imaging"},{"key":"6481_CR49","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S1474-4422(11)70077-1","volume":"10","author":"H Barthel","year":"2011","unstructured":"Barthel H, Gertz H-J, Dresel S, et al. Cerebral amyloid-\u03b2 PET with florbetaben (18F) in patients with Alzheimer\u2019s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10:424\u201335.","journal-title":"Lancet Neurol"},{"key":"6481_CR50","doi-asserted-by":"publisher","first-page":"276","DOI":"10.11613\/BM.2012.031","volume":"22","author":"ML McHugh","year":"2012","unstructured":"McHugh ML. Interrater reliability: the kappa statistic. Biochem Medica. 2012;22:276\u201382.","journal-title":"Biochem Medica"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06481-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-023-06481-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06481-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T11:48:09Z","timestamp":1705578489000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-023-06481-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,28]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["6481"],"URL":"https:\/\/doi.org\/10.1007\/s00259-023-06481-0","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,28]]},"assertion":[{"value":"11 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"FB is supported by the NIHR biomedical research centre at UCLH. He is steering committee or Data Safety Monitoring Board member for Biogen, Merck, ATRI\/ACTC and Prothena. Consultant for Roche, Celltrion, Rewind Therapeutics, Merck, IXICO, Jansen, Combinostics and has research agreements with Merck, Biogen, GE Healthcare, Roche. He is also co-founder and shareholder of Queen Square Analytics LTD. JDG holds a \u2018Ram\u00f3n y Cajal\u2019 fellowship (RYC-2013\u201313054) from the Spanish Ministry of Science, Innovation and Universities, has received research support from GE Healthcare, Roche Diagnostics and Hoffmann\u2013La Roche, and speaker or consultant fees from Philips Nederlands and Roche Diagnostics. VG reports grants from the Swiss National Science Foundation (projects:320030_169876, 320030_185028 and IZSEZ0_188355), the Velux foundation (project:1123) and she received financial support for research and\/or speaker fees through her institution from Siemens Healthineers, GE Healthcare, Life Molecular Imaging, Cerveau Technologies, Roche, Merck. MS has served on advisory boards for Servier, Roche and Novo Nordisk (outside scope of submitted work) and receives funding from the Knut and Alice Wallenberg Foundation (Wallenberg Centre for Molecular and Translational Medicine; KAW2014.0363, KAW2023.0371), the Swedish Research Council (2017\u201302869, 2021\u201302678 and 2021\u201306545), the Swedish State under the Agreement Between the Swedish Government and the County Councils, the ALF-agreement (ALFGBG-813971 and ALFGBG-965326), the Swedish Brain Foundation (FO2021-0311) and the Swedish Alzheimer Foundation (AF-740191). GBF is funded by the following private donors under the supervision of the Private Foundation of Geneva University Hospitals: A.P.R.A.\u2014Association Suisse pour la Recherche sur la Maladie d\u2019Alzheimer, Gen\u00e8ve; Fondation Segr\u00e9, Gen\u00e8ve; Race Against Dementia Foundation, London, UK; Fondation Child Care, Gen\u00e8ve; Fondation Edmond J. Safra, Gen\u00e8ve; FondationMinkoff, Gen\u00e8ve; Fondazione Agusta, Lugano; McCall Macbain Foundation, Canada; Nicole et Ren\u00e9 Keller, Gen\u00e8ve; Fondation AETAS, Gen\u00e8ve. GBF has received funding for research projects from: H2020, Innovative Medicines Initiative (IMI), IMI2, Swiss National Science Foundation, VELUX Foundation; has received unrestricted grants and support for event organisation from ROCHE Pharmaceuticals, OM Pharma, EISAI Pharmaceuticals, Biogen Pharmaceuticals. The Clinical Research Center, at Geneva University Hospital and Faculty of Medicine provides valuable support for regulatory submissions and data management, and the Biobank at Geneva University Hospital for biofluid processing and storage.\u00a0LC\u00a0has received research support from GE Healthcare and Springer Healthcare (funded by Eli Lilly). Both paid to the institution.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}